Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
109 hedge funds and large institutions have $812M invested in Epizyme, Inc in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 18 closing their positions.
66% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 29
2% more call options, than puts
Call options by funds: $754K | Put options by funds: $739K
0% more funds holding
Funds holding: 109 → 109 (0)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
24% less capital invested
Capital invested by funds: $1.06B → $812M (-$252M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$21.6M |
| 2 |
DM
Deerfield Management
New York
|
+$10.6M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
+$8.97M |
| 4 |
Morgan Stanley
New York
|
+$6.49M |
| 5 |
BlackRock
New York
|
+$6.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$17M |
| 3 |
Millennium Management
New York
|
-$12.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.78M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.5M |
EPZM Hedge Fund Activity: Q2 2018 in Review
109 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2018, worth a combined $812M — down 24% from $1.06B a quarter earlier.
Fund positioning in EPZM was balanced in Q2 2018: 18 funds opened new positions, 18 closed out, 48 added to existing stakes and 29 trimmed.
The largest buyer was Primecap Management, adding an estimated $21.6M. The largest seller was Fidelity Investments, cutting an estimated $20.7M.
- 109 institutional investors held Epizyme, Inc (EPZM) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $812M of Epizyme, Inc stock for Q2 2018, down 24% quarter-over-quarter.
- 18 funds opened new Epizyme, Inc positions in Q2 2018 and 18 closed out, a net change of 0 holders.
- The largest Epizyme, Inc buyer in Q2 2018 was Primecap Management, an estimated $21.6M added.
- The largest Epizyme, Inc seller in Q2 2018 was Fidelity Investments, an estimated $20.7M sold.
Based on aggregated 13F filings for Q2 2018.